Compare · GRPH vs MNMD
GRPH vs MNMD
Side-by-side comparison of Graphite Bio Inc. (GRPH) and Mind Medicine (MindMed) Inc. (MNMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRPH and MNMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- Both have 16 recent analyst ratings on file.
- Company
- Graphite Bio Inc.
- Mind Medicine (MindMed) Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- +19.56%
- 1Y return
- -
- +23.45%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 16
- 16
Graphite Bio Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest GRPH
- Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form 10-Q filed by Graphite Bio Inc.
- Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form EFFECT filed by Graphite Bio Inc.
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)
- Graphite Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-1 filed by Graphite Bio Inc.
- New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits